DexCom (DXCM) is back in focus after first quarter 2026 earnings, reporting revenue of US$1.19b and net income of US$199.5m, alongside reaffirmed full year revenue guidance and margin upgrades.

Despite the strong first quarter results, DexCom's recent share price performance has been soft, with a 90 day share price return of 15.41% and a 1 year total shareholder return of 24.83%. This signals fading momentum even as product launches and coverage wins continue.

If earnings news has you reassessing your watchlist, it could be worth checking a curated set of healthcare focused AI names through our 33 healthcare AI stocks

With DexCom shares down over the past year despite strong Q1 numbers and reaffirmed 2026 guidance, the key question now is whether the recent weakness leaves the stock undervalued or if the market is already pricing in future growth potential.

Most Popular Narrative: 29.4% Undervalued

DexCom's most followed narrative pegs fair value at $86.88 versus the last close of $61.35, framing the current weakness as a sizable valuation gap to test.

The recent expansion of insurance reimbursement for type 2 non-insulin diabetes patients, now covering nearly 6 million lives across the three largest U.S. PBMs, opens a large, previously untapped segment of DexCom's addressable market, driving new patient growth and supporting robust multi-year revenue expansion. Growing global recognition of CGM efficacy, with recent clinical trial evidence and expanded coverage in international markets (for example, France, Japan, and Ontario, Canada), positions DexCom to penetrate underpenetrated regions and diversify revenue streams, creating sustainable top-line growth.

Curious what kind of revenue profile, margin structure, and future earnings base support that higher fair value, and how a single discount rate pulls it all together?

Result: Fair Value of $86.88 (UNDERVALUED)

However, you still need to weigh execution risks, as potential CMS competitive bidding pressure and intensifying CGM competition are both capable of challenging the upbeat valuation story.

Next Steps

With sentiment split between upside potential and execution risk, it makes sense to look at the numbers yourself and move before the crowd settles on a view. To round out your own work, check the 4 key rewards

Ready to hunt for your next idea?

If DexCom has your attention, do not stop here. The market is full of other opportunities that fit different goals and risk levels.

• Target dependable income by scanning a focused set of high yield payers through the 13 dividend fortresses.
• Spot potential bargains early by searching companies that pair quality fundamentals with appealing pricing using the 50 high quality undervalued stocks.
• Prioritise resilience by filtering for businesses with stronger balance sheets and healthier finances through the solid balance sheet and fundamentals stocks screener (44 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.